Survodutide

A dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Survodutide leverages glucagon receptor activation to increase energy expenditure while using GLP-1 agonism for appetite suppression, with a particular focus on metabolic-associated steatohepatitis (MASH) and liver health.

• GLP-1 receptor agonism reduces appetite and improves glycemic control
• Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure
• Dual action promotes negative energy balance through complementary pathways

• Personal or family history of medullary thyroid carcinoma
• MEN2 syndrome
• Severe hepatic impairment
• History of pancreatitis
• Pregnancy or breastfeeding

Store at 2–8°C (36–46°F), protected from light. Follow manufacturer guidelines once commercially available.

Phase 2 data showed survodutide produced up to 18.7% weight loss at 46 weeks and significant improvements in MASH histological endpoints, including fibrosis. The compound demonstrated 83% relative reduction in liver fat content. Phase 3 trials are ongoing for both obesity and MASH indications. Boehringer Ingelheim positions survodutide as a liver-focused metabolic therapy with strong weight loss as a co-benefit.